Pegaspargase is named as a drug or biological intervention in 5 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Fudan University (2), Beijing Tongren Hospital (1) and Mingzhi Zhang (1). Registered phases: Phase 2 and Phase 1/2. Conditions studied include Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type; NKTCL; T-lymphoblastic Lymphoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06314334 | Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (ClinicalTrials.gov ↗) Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type |
Phase 2 | Recruiting |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma (ClinicalTrials.gov ↗) Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma |
Phase 1/2 | Recruiting |
| NCT06559553 | "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL (ClinicalTrials.gov ↗) NKTCL, Selinexor |
Phase 1/2 | Recruiting |
| NCT07574528 | A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma (ClinicalTrials.gov ↗) NKTCL |
Phase 2 | Not yet open |
| NCT07768943 | GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma (ClinicalTrials.gov ↗) Natural Killer/T-cell Lymphoma |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | 2 |
| NKTCL | 2 |
| T-lymphoblastic Lymphoma | 1 |
| Selinexor | 1 |
| Natural Killer/T-cell Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Fudan University | 2 |
| Beijing Tongren Hospital | 1 |
| Mingzhi Zhang | 1 |
| Sun Yat-sen University | 1 |
| Register | Pegaspargase trials |
|---|---|
| Clinical trials in China | 5 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pegaspargase works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pegaspargase (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.